[go: up one dir, main page]

MX2020012932A - Nuevos compuestos para diagnostico. - Google Patents

Nuevos compuestos para diagnostico.

Info

Publication number
MX2020012932A
MX2020012932A MX2020012932A MX2020012932A MX2020012932A MX 2020012932 A MX2020012932 A MX 2020012932A MX 2020012932 A MX2020012932 A MX 2020012932A MX 2020012932 A MX2020012932 A MX 2020012932A MX 2020012932 A MX2020012932 A MX 2020012932A
Authority
MX
Mexico
Prior art keywords
synuclein
diagnosis
disorder
monitoring
disease
Prior art date
Application number
MX2020012932A
Other languages
English (en)
Inventor
Jérôme Molette
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of MX2020012932A publication Critical patent/MX2020012932A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a nuevos compuestos que pueden emplearse en el diagnóstico, seguimiento de la progresión de enfermedad o seguimiento de la actividad farmacológica de un grupo de trastornos y anomalías asociadas con la alfa-sinucleína (a-sinucleína, A-sinucleína, aSinucleína, a-sinucleína, A-syn, a-syn, aSyn, SNCA, componente beta no amiloide de las placas amiloides de la enfermedad de Alzheimer (EA), agregados de componente no A4 del precursor amiloide, NACP) que incluyen, entre otros, cuerpos de Lewy y/o neuritas de Lewy, tal como la enfermedad de Parkinson (EP). Los presentes compuestos son particularmente útiles en el diagnóstico del estado preclínico de ese trastorno, monitoreando el trastorno residual o prediciendo la capacidad de respuesta de un paciente que padezca ese trastorno al tratamiento con un determinado medicamento.
MX2020012932A 2018-06-08 2019-06-07 Nuevos compuestos para diagnostico. MX2020012932A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18176768 2018-06-08
EP18210495 2018-12-05
PCT/EP2019/065031 WO2019234243A1 (en) 2018-06-08 2019-06-07 Novel compounds for diagnosis

Publications (1)

Publication Number Publication Date
MX2020012932A true MX2020012932A (es) 2021-02-15

Family

ID=66912798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012932A MX2020012932A (es) 2018-06-08 2019-06-07 Nuevos compuestos para diagnostico.

Country Status (11)

Country Link
US (1) US20210252175A1 (es)
EP (1) EP3802548B1 (es)
JP (1) JP7397492B2 (es)
KR (1) KR20210020072A (es)
CN (1) CN112533928A (es)
CA (1) CA3102038A1 (es)
ES (1) ES2988770T3 (es)
IL (1) IL279219B2 (es)
MX (1) MX2020012932A (es)
SG (1) SG11202012150UA (es)
WO (1) WO2019234243A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220397577A1 (en) 2019-10-01 2022-12-15 Ac Immune Sa Micro-Radiobinding Assays for Ligand Screening
KR20230008183A (ko) 2020-05-07 2023-01-13 에이씨 이뮨 에스에이 진단을 위한 신규한 화합물
BR112023002139A2 (pt) * 2020-08-06 2023-04-18 Chdi Foundation Inc Compostos de heterobiarila e agentes de imageamento para proteína huntingtina
AU2022387830A1 (en) 2021-11-10 2024-05-23 Ac Immune Sa Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis
EP4430046A1 (en) 2021-11-10 2024-09-18 AC Immune SA 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis
WO2023083961A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
CN116262744A (zh) * 2021-12-13 2023-06-16 复旦大学 用于α-突触核蛋白聚集体成像的小分子探针
WO2024126842A1 (en) 2022-12-16 2024-06-20 Ac Immune Sa Novel compounds for diagnosis
WO2024126840A1 (en) 2022-12-16 2024-06-20 Ac Immune Sa Novel compounds for diagnosis
WO2024236059A1 (en) * 2023-05-15 2024-11-21 Ac Immune Sa Novel compounds for the treatment of disease associated with alpha-synuclein aggregates
WO2025037013A1 (en) 2023-08-16 2025-02-20 Ac Immune Sa Diagnostic compounds that bind to alpha-synuclein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
AU2009260519A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
US20110178070A1 (en) 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
KR20110046503A (ko) 2008-07-24 2011-05-04 지멘스 메디컬 솔루션즈 유에스에이, 인크. Ａｄ 병인을 확인하기에 유용한 영상화제
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
DK2558446T5 (da) 2010-04-16 2019-12-09 Ac Immune Sa Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner
DE102010045797A1 (de) 2010-09-20 2012-03-22 Klinikum Darmstadt Gmbh Verbindungen für die Diagnostik neurodegenerativer Erkrankungen am Riechepithel
US9845327B2 (en) * 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
US20130046093A1 (en) 2011-08-18 2013-02-21 Korea Institute Of Science And Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
EP2999701B1 (en) 2013-05-23 2017-04-12 Hoffmann-La Roche Inc. 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
SG11201701600QA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
WO2016057812A1 (en) 2014-10-08 2016-04-14 Texas Children's Hosptial Mri imaging of amyloid plaque using liposomes
EP3961216B1 (en) 2014-11-14 2024-02-14 United Arab Emirates University Dihydromyricetin for use as imaging agent
NZ746901A (en) * 2016-03-11 2023-06-30 Ac Immune Sa Bicyclic compounds for diagnosis and therapy

Also Published As

Publication number Publication date
ES2988770T3 (es) 2024-11-21
CA3102038A1 (en) 2019-12-12
CN112533928A (zh) 2021-03-19
KR20210020072A (ko) 2021-02-23
EP3802548B1 (en) 2024-08-14
WO2019234243A1 (en) 2019-12-12
SG11202012150UA (en) 2021-01-28
JP7397492B2 (ja) 2023-12-13
JP2021525742A (ja) 2021-09-27
US20210252175A1 (en) 2021-08-19
IL279219B1 (en) 2024-04-01
EP3802548A1 (en) 2021-04-14
IL279219B2 (en) 2024-08-01
IL279219A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
MX2020012932A (es) Nuevos compuestos para diagnostico.
EP4001277A3 (en) Bicyclic compounds for diagnosis and therapy
Blesa et al. Compensatory mechanisms in Parkinson's disease: circuits adaptations and role in disease modification
MX2021012608A (es) Nuevas moleculas para terapia y diagnostico.
Wuwongse et al. The putative neurodegenerative links between depression and Alzheimer's disease
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
MX2023001299A (es) Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
MY164579A (en) Safe and functional humanized antibodies
MX2018000696A (es) Anticuerpos humanizados anti-beta-amiloide piroglutamados.
WO2016087944A3 (en) Method for treating alzheimer's disease
MY171300A (en) Pharmaceutical composition
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
JP2013534256A5 (es)
RU2017103446A (ru) УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ
EP3405215A4 (en) METHOD FOR THE TREATMENT OF MORBUS DANON AND OTHER AUTOPHAGIC DISEASES
MX2014010268A (es) Metodos, aparatos y sistemas para el diagnostico y tratamiento de trastornos del estado de animo.
EP3956346A4 (en) NEW RADIOLABALED DIAGNOSTIC AND THERAPEUTIC COMPOUNDS TARGETING CXCR4
Sinforiani et al. Hallucinations and sleep–wake cycle in Alzheimer's disease: a questionnaire-based study in 218 patients
MX2022004812A (es) Sistemas de virus adeno-asociados (aav) para el tratamiento de enfermedades o trastornos neurodegenerativos asociados a la progranulina.
JP2009178162A5 (es)
PH12012501882A1 (en) Humanized antibody against amyloid beta
EP4356967A3 (en) Compounds for use as imaging agents
MX2020007986A (es) Anticuerpos humanizados y desinmunizados.
EP2854945A4 (en) DEVICES FOR TREATMENT AND / OR DIAGNOSIS OF ENGINE-RELATED NEUROLOGICAL DISEASES
WO2019070813A3 (en) Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder